This link will take you to a page that’s not on LinkedIn

Because this is an external link, we’re unable to verify it for safety.

https://www.abelzeta.com/abelzeta-announces-late-breaking-poster-presentation-at-acr-convergence-2025-of-first-in-human-phase-i-trial-of-anti-cd20-bcma-bispecific-car-t-therapy-in-patients-with-refractory-autoimmune-diseases/